Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Launch of new podcast series Trusting the Science

The Oxford Vaccine Group is celebrating 30 years of life-saving vaccine development with the release of a new podcast series of conversations called Trusting the Science. This is the second series of The Oxford Colloquy - discourses hosted by Professor Sir Andrew Pollard who has been Director of the group for over 20 years - and each episode delves into the crucial role that science plays in our understanding of health and immunity.

Throughout the series, Professor Pollard interviews leading global experts – starting with Dr. Anthony Fauci, Chief Scientific Advisor to seven US Presidents – on their scientific journey, the discoveries they have made, and their thoughts on how we can build and maintain the public’s trust in scientific knowledge at a time of misinformation and cynicism.

The first episode airs today, Thursday 19th September, and is available on all major podcast platforms, including Spotify and Apple Podcasts, as well as a video version on YouTube. It also available via Oxford University Podcasts. 

Professor Pollard said: “This year marks the Oxford Vaccine Group’s 30th anniversary since its establishment in 1994 and these conversations are dedicated to exploring the world of science by finding out about the facts, stories, and experiences of the people that make it all possible. They are designed to inspire listeners with thoughtful and insightful perspectives on science and science policy, as well as to record the fascinating journeys of some of the most distinguished physicians and scientists of our time and those involved in communicating science and policymakers.”

 Following this first launch episode, the podcast will release new episodes on the last Thursday of every month starting on 26th September 2024. Notable guests on the series include:

  • Dame Sally Davies, former government Chief Medical Officer and UK Special envoy on AMR, who talks about her journey into medicine, legislating for public health, and the complexities of tackling antimicrobial resistance.
  • Professor Peter Doherty, Nobel laureate, immunologist and Australian National Treasure, on his controversial discovery of killer T cells, ensuing notoriety, and the accidental tweet that actually made him famous.  
  • Fiona Fox OBE, Honorary Fellow of the Royal Society and Chief executive of the Science Media Centre, on improving the quality of the science in our news, the politics of the truth and the importance of good communicators in the media.

Listeners can subscribe to “The Oxford Colloquy” at Homepage | University of Oxford Podcasts as well as on Spotify and Apple Podcasts.

Similar stories

Oxford University and King’s College London Join IMPACT Network Study to Advance Understanding of Profound Autism

The University of Oxford and King’s College London (King’s) have joined the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international collaboration of sites working together to accelerate clinical trial readiness and therapeutic development for autism through a large-scale natural history and clinical endpoint study.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.

University of Oxford launches new public awareness campaign for Neurodevelopmental Disorders

The Department of Paediatrics at the University of Oxford today announces the launch of Genes, Brains, and Breakthroughs, a new educational campaign designed to raise public awareness and understanding of neurodevelopmental disorders through a series of accessible, family-informed video resources.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

Breakthrough study moves newborn screening for SMA towards nationwide rollout

A major national study led by researchers in the Department of Paediatrics, to evaluate newborn screening for spinal muscular atrophy (SMA) has been funded by the National Institute for Health and Care Research (NIHR), marking a significant milestone towards the potential introduction of SMA screening across the UK.

University of Oxford and Serum Institute of India Agree Licence to Advance the Next-Generation Multi-Stage Malaria Vaccine Candidate Component R78C

The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, which has been developed by the Draper Lab in the Department of Paediatrics, and is based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.